Subscribe to Search results

The reason for the DHSS' suggestion that patients be kept on one type or one batch of concentrate was to simplify analysis and presentation of results, increase the chances of identifying icterogenic material and permit the withdrawal of icterogenic bottles.

Published on:

Dr Craske wrote to the Small Grants Secretariat recording that whilst haemophilia centre directors had agreed in theory to maintaining patients on single batches or brands, the shortage of Factor VIII, large numbers of patients under treatment and the cost of maintaining stocks of Factor VIII meant that they did not consider it to be a practical policy to stick rigidly to this regime.

Published on:

Dr Mary Collins on behalf of the DHSS said regarding self-sufficiency that there was no limit on the amount of commercial material which Haemophilia Centres could receive.

Published on:

In a meeting of the haemophilia centre directors, it was reported that the 1976 and 1977 annual returns from haemophilia centres demonstrated that an increasingly large amount of commercial Factor 8 concentrate was being used by centres.

Published on:

The Hepatitis Working Party agreed to continue the study on the Oxford Haemophiliacs to obtain more evidence of the relationship of transaminitis and overt chronic liver disease to mortality.

Published on:

There was little discussion of issues relating to hepatitis at the haemophilia reference centre directors'

Published on:

Dr Craske gave a presentation on the work of the Hepatitis Working Party at the UKHCDO annual meeting

Published on:

The Hepatitis Working Party agreed more information was needed on the risk to patients of developing chronic NANBH, by prospectively following patients first exposed to concentrate or other products, such as people with mild haemophilia undergoing non-emergency surgery.

Published on:

Dr Peter Jones became director of the Newcastle Haemophilia Centre.

Published on:

Dr Peter Jones believed the major part of his responsibility was "a regional commitment to the care of children and adults with haemophilia".

Published on:

There were 43 patients on home therapy, with a mean Factor 8 usage of 18,796 units per patient per year at Newcastle Haemophilia Centre.

Published on:

Prophylaxis was a feature of treatment policy at Newcastle Haemophilia Centre.

Published on:

Dr Peter Jones had no doubt that haemophiliacs exposed to multi donor concentrates were infected with non-A non-B hepatitis and that a substantial number would go on to develop chronic liver disease.

Published on:

Dr Peter Jones suggested AIDS in haemophilia patients was brought to the attention of haemophilia centre directors by Professor Bloom at a meeting of the Haemophilia Reference Centre Directors.

Published on:

Dr Peter Jones was joined by Dr Peter Hamilton as co-director of the Newcastle Haemophilia Centre.

Published on:

Dr Jones' "Guidelines for the Organisation of a Haemophilia Centre" recorded that "within our geographical region, which has a population of 3.3 million, the home therapy programme is run from the Newcastle Centre and all patients are followed up there by the core team."

Published on:

In a letter from Dr Jones to Dr Sackwood, it was noted that 23 patients were on home therapy in the Newcastle area.

Published on:

Dr Jones suggested in his statement to the Inquiry, that cryoprecipitate was the treatment of choice until 1973, "when sufficient Factor VIII became available".

Published on:

Dr Jones stated that the introduction of concentrates allowed the development of home therapy and eventually prophylactic treatment.

Published on:

Dr Jones suggested that the Newcastle centre's policy was to encourage both home and prophylaxis treatment.

Published on: